Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by principal investigator, Dr Roberto Diletti (Thoraxcenter, Erasmus Medical Center, NL) to explore the findings of the BIOVASC Trial.

The primary objective of the BIOVASC Trial was to investigate whether an immediate complete revascularization is non inferior to a staged complete revascularization strategy.

The trial results presented at ACC.23 showed that in ACS patients with multivessel coronary artery disease, an immediate complete revascularization strategy was non inferior to a staged complete revascularization for the composite primary outcome and was associated with lower rates of myocardial infarction and unplanned ischaemia driven revascularization at one-year follow-up.

Recorded on site at ACC 2023, New Orleans.

Visit Radcliffe Cardiology:

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook:
Follow us on Twitter:

Чтобы скачать видео "ACC 23 Late-Breaker Discussion: The BIOVASC Trial" передвинте ползунок вправо